Supplementary Table 1 from Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer

Marín-Aguilera, Mercedes; Codony-Servat, Jordi; Reig, Òscar; Lozano, Juan José; Fernández, Pedro Luis; Pereira, María Verónica; Jiménez, Natalia; Donovan, Michael; Puig, Pere; Mengual, Lourdes; Bermudo, Raquel; Font, Albert; Gallardo, Enrique; Ribal, María José; Alcaraz, Antonio; Gascón, Pere; Mellado, Begoña

doi:10.1158/1535-7163.22501402.v1

15357163mct130775-sup-tab.pdf (72.46 kB)

Supplementary Table 1 from Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer

journal contribution

posted on 2023-04-03, 14:13 authored by Mercedes Marín-Aguilera, Jordi Codony-Servat, Òscar Reig, Juan José Lozano, Pedro Luis Fernández, María Verónica Pereira, Natalia Jiménez, Michael Donovan, Pere Puig, Lourdes Mengual, Raquel Bermudo, Albert Font, Enrique Gallardo, María José Ribal, Antonio Alcaraz, Pere Gascón, Begoña Mellado

PDF - 72K, Genes expression values by qRT-PCR in treated patients vs non-treated patients; TLDA: TaqMan Low Density Arrays; FDR: False Discovery Rate.

History

ARTICLE ABSTRACT

Molecular characterization of radical prostatectomy specimens after systemic therapy may identify a gene expression profile for resistance to therapy. This study assessed tumor cells from patients with prostate cancer participating in a phase II neoadjuvant docetaxel and androgen deprivation trial to identify mediators of resistance. Transcriptional level of 93 genes from a docetaxel-resistant prostate cancer cell lines microarray study was analyzed by TaqMan low-density arrays in tumors from patients with high-risk localized prostate cancer (36 surgically treated, 28 with neoadjuvant docetaxel + androgen deprivation). Gene expression was compared between groups and correlated with clinical outcome. VIM, AR and RELA were validated by immunohistochemistry. CD44 and ZEB1 expression was tested by immunofluorescence in cells and tumor samples. Parental and docetaxel-resistant castration-resistant prostate cancer cell lines were tested for epithelial-to-mesenchymal transition (EMT) markers before and after docetaxel exposure. Reversion of EMT phenotype was investigated as a docetaxel resistance reversion strategy. Expression of 63 (67.7%) genes differed between groups (P < 0.05), including genes related to androgen receptor, NF-κB transcription factor, and EMT. Increased expression of EMT markers correlated with radiologic relapse. Docetaxel-resistant cells had increased EMT and stem-like cell markers expression. ZEB1 siRNA transfection reverted docetaxel resistance and reduced CD44 expression in DU-145R and PC-3R. Before docetaxel exposure, a selected CD44+ subpopulation of PC-3 cells exhibited EMT phenotype and intrinsic docetaxel resistance; ZEB1/CD44+ subpopulations were found in tumor cell lines and primary tumors; this correlated with aggressive clinical behavior. This study identifies genes potentially related to chemotherapy resistance and supports evidence of the EMT role in docetaxel resistance and adverse clinical behavior in early prostate cancer. Mol Cancer Ther; 13(5); 1270–84. ©2014 AACR.